https://pressroom.prlog.org/signablok/ About SignaBlok, Inc. - SignaBlok is developing a new class of therapies that can have broad potential to treat and prevent a wide range of serious diseases with unmet needs. The Company is also developing a nanotechnology for targeted delivery of drugs and imaging agents. https://www.prlog.org/12445242-signablok-to-highlight-school-therapeutic-peptides-at-the-2015-essential-protein-engineering-summit.html Preclinical studies of novel peptide inhibitors (SCHOOL peptides) will be presented in an oral session. Presentation will highlight company's approach to targeted peptide delivery and support development of programs in oncology, sepsis and arthritis.Mon, 13 Apr 2015 14:43:23 GMT https://www.prlog.org/12375800-signablok-awarded-nih-grant-to-test-new-therapy-for-rheumatoid-arthritis.html SignaBlok, Inc. was awarded a new $223,013 SBIR Phase I grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to develop a novel approach for targeted therapy of rheumatoid arthritis.Thu, 25 Sep 2014 14:55:18 GMT https://www.prlog.org/12353841-signablok-wins-134m-nih-phase-ii-grant-to-advance-new-nanotechnology-for-atherosclerosis-imaging.html SignaBlok, Inc. was awarded a new NIH SBIR Phase II grant totaling $1.34 million for continuing development of new nanotechnology-based atherosclerosis imaging. This award follows on the success of work completed during the Phase I grant.Tue, 29 Jul 2014 21:03:17 GMT https://www.prlog.org/12211806-signablok-achieves-key-in-vivo-proof-of-concept-for-treatment-of-cancer-and-sepsis.html Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and SepsisTue, 17 Sep 2013 13:41:38 GMT https://www.prlog.org/12166791-signablok-announces-notice-of-patent-allowance-on-trem-1-peptide-therapeutics-for-sepsis-and-cancer.html SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, received a Notice of Allowance of Key U.S. Patent for novel and first-in-class agents in sepsis and cancerMon, 01 Jul 2013 12:56:31 GMT https://www.prlog.org/11988113-signablok-awarded-nci-grant-to-test-new-approach-to-lung-cancer-treatment.html SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer.Mon, 01 Oct 2012 13:42:25 GMT https://www.prlog.org/11920643-signablok-awarded-nih-grant-to-develop-new-nanotechnology-for-diagnostic-imaging-of-atherosclerosis.html SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis.Tue, 10 Jul 2012 16:07:08 GMT https://www.prlog.org/11768685-signablok-awarded-darpa-contract-to-support-new-technology-to-combat-sepsis.html SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning).Tue, 10 Jan 2012 20:44:10 GMT